1. Anti-infection
    Metabolic Enzyme/Protease
  2. HCV
    HCV Protease

Vaniprevir (Synonyms: MK-7009; MK7009; MK 7009)

Cat. No.: HY-10243
Handling Instructions

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

For research use only. We do not sell to patients.
Vaniprevir Chemical Structure

Vaniprevir Chemical Structure

CAS No. : 923590-37-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO $417 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. IC50 Value: Target: HCV NS3/4A Protease; HCV vaniprevir (MK-7009) is a macrocyclic hepatitis C virus NS3/4a protease inhibitor, is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes. vaniprevir (MK-7009) has good plasma exposure and excellent liver exposure in multiple species.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00518622 Merck Sharp & Dohme Corp. Hepatitis C July 2007 Phase 1
NCT00895882 Merck Sharp & Dohme Corp. Chronic Genotype 1 Hepatitis C Virus Infection November 2010 Phase 2
NCT00954993 Merck Sharp & Dohme Corp. Chronic Hepatitis C Infection January 2010 Phase 1
NCT01010906 Merck Sharp & Dohme Corp. Hepatitis C July 2009 Phase 1
NCT01405560 Merck Sharp & Dohme Corp. Hepatitis C, Chronic September 2011 Phase 3
NCT01678131 Merck Sharp & Dohme Corp. Chronic Hepatitis C October 2012 Phase 1
NCT01405937 Merck Sharp & Dohme Corp. Hepatitis C, Chronic August 2011 Phase 3
NCT00704405 Merck Sharp & Dohme Corp. Hepatitis C, Chronic March 2009 Phase 2
NCT00704184 Merck Sharp & Dohme Corp. Hepatitis C July 2008 Phase 2
NCT01370642 Merck Sharp & Dohme Corp. Hepatitis C, Chronic June 2011 Phase 3
NCT00880763 Merck Sharp & Dohme Corp. Hepatitis C April 2009 Phase 2
NCT00943761 Merck Sharp & Dohme Corp. Hepatitis C, Chronic October 2009 Phase 2
View MoreCollapse
References
M.Wt

757.94

Formula

C₃₈H₅₅N₅O₉S

CAS No.

923590-37-8

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vaniprevir
Cat. No.:
HY-10243
Quantity: